Syndax Announces Private Placement of $250.0 Million of Convertible Senior Notes
Syndax Pharmaceuticals has entered into a private placement agreement to issue $250 million of 2.25% Convertible Senior Notes due in 2031. The proceeds will be used for general corporate purposes, including R&D, commercialization, and business development. The notes carry an initial conversion price representing a 35% premium over recent trading pr…